Source comparison
The Regulatory and Practical Differences Between PT-141 vs Vyleesi
Vyleesi is an FDA-approved drug product manufactured by Palatin Technologies under strict Good Manufacturing Practices (GMP), with every batch tested for potency, sterility, and endotoxin levels before distribution. It's dispensed as a single-use, pre-filled a
This comparison does not assign a generated winner or score.
- Vyleesi is an FDA-approved drug product manufactured by Palatin Technologies under strict Good Manufacturing Practices (GMP), with every batch tested for potency, sterility, and endotoxin levels before distribution. It's dispensed as a single-use, pre-filled autoinjector pen containing 1.75mg bremelanotide in a sterile aqueous solution. Insurance coverage varies. Some plans classify it as a lifestyle drug and deny coverage entirely, while others cover it with prior authorization. Cash price without insurance typically ranges from $800–$900 per injection, or $2,400–$3,600 for a typical monthly supply of 3–4 doses.
- PT-141, by contrast, is not FDA-approved as a finished drug product. It's prepared by FDA-registered 503B outsourcing facilities or state-licensed compounding pharmacies, which are permitted to compound medications using bulk active pharmaceutical ingredients (APIs) when a prescriber determines compounding is medically necessary. Compounded bremelanotide is sold as lyophilized powder in vials, typically 10mg or 20mg per vial, which the patient reconstitutes with bacteriostatic water before drawing and injecting subcutaneous doses. Cost is dramatically lower. $80–$150 per dose depending on supplier and volume purchased.
- The trade-off is traceability and oversight. Vyleesi undergoes FDA batch release testing. If contamination or potency deviation occurs, a formal recall is issued. Compounded PT-141 is subject to state pharmacy board inspection and USP Chapter 797 sterile compounding standards, but individual batch testing isn't mandatory unless the facility voluntarily participates in third-party verification programs. Most reputable 503B facilities. Including those supplying Real Peptides. Publish certificates of analysis (COAs) showing HPLC purity and endotoxin testing, but this is voluntary industry practice, not regulatory requirement.
- Patients choosing PT-141 vs Vyleesi are effectively choosing between guaranteed FDA oversight with higher cost and convenience, versus lower cost with self-administration responsibility and reliance on compounding pharmacy reputation. Neither is inherently unsafe. The risk profile depends on the specific compounder's quality control practices.